Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

11/12/24 4:40:26 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GOSS alert in real time by email

SC 13G/A 1 d910514dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934*

(Amendment No. 2)

Gossamer Bio, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

38341P102

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Invus Public Equities, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 13,474,350
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 13,474,350
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,474,350
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

2


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Invus Public Equities Advisors, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 13,474,350
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 13,474,350
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,474,350
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

3


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Invus Global Management, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 13,474,350
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 13,474,350
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,474,350
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

4


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Siren, L.L.C.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 13,474,350
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 13,474,350
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,474,350
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

5


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Avicenna Life Sci Master Fund LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 857,172
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 857,172
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 857,172
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

6


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Avicenna Life Sci Master GP LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 857,172
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 857,172
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 857,172
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

7


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Ulys, L.L.C.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 857,172
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 857,172
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 857,172
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

8


CUSIP No. 38341P102		13G


1		NAMES OF REPORTING PERSONS Raymond Debbane
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Panama


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 14,331,522
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 14,331,522
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 14,331,522
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.3%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

9

Item 1(a).

Name of Issuer:

Gossamer Bio, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

3013 Science Park Road, San Diego, California 92121

Item 2(a).

Name of Person Filing:

Item 2(b).

Address of Principal Business Office or, if none, Residence:

Item 2(c).

Citizenship:

(i) Invus Public Equities, L.P. (“Invus Public Equities”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Bermuda limited partnership

(ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(iii) Invus Global Management, LLC (“Global Management”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(iv) Siren, L.L.C. (“Siren”)

c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(v) Avicenna Life Sci Master Fund LP (“Avicenna Fund”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Cayman Islands limited partnership

(vi) Avicenna Life Sci Master GP LLC (“Avicenna GP”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(vii) Ulys, L.L.C. (“Ulys”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(viii) Mr. Raymond Debbane

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Panama

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 per share (the “Common Stock” or “Shares”)

Item 2(e).

CUSIP Number:

38341P102

10

Item 3.

If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

This Item 3 is not applicable.

Item 4.

Ownership.

As of September 30, 2024, Invus Public Equities directly held 12,424,438 Shares, call options exercisable for 207,000 Shares, with an exercise price of $2.00 per Share and expiration date of January 17, 2025 and warrants (the “Warrants”) to purchase up to 842,912 Shares, with an exercise price of $2.04 per Share and expiration date of July 24, 2028 and Avicenna Fund directly held 857,172 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares beneficially held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.

(b) Percent of class:

As of September 30, 2024, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 226,227,259 Shares outstanding as of August 7, 2024 based on information set forth in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2024, plus (ii) 842,912 Shares issuable upon exercise of the Warrants.

(c) Number of shares as to which each Reporting Person has:

(i)

Sole power to vote or to direct the vote:

See each cover page hereof.

(ii)

Shared power to vote or to direct the vote:

See each cover page hereof.

(iii)

Sole power to dispose or to direct the disposition of:

See each cover page hereof.

(iv)

Shared power to dispose or to direct the disposition of:

See each cover page hereof.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

This Item 6 is not applicable.

11

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

This Item 7 is not applicable.

Item 8.

Identification and Classification of Members of the Group.

This Item 8 is not applicable.

Item 9.

Notice of Dissolution of Group.

This Item 9 is not applicable.

Item 10.

Certification.

Each of the Reporting Persons hereby makes the following certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 12, 2024


INVUS PUBLIC EQUITIES, L.P.

By:		INVUS PUBLIC EQUITIES ADVISORS,
		LLC, its general partner

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS PUBLIC EQUITIES ADVISORS, LLC

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS GLOBAL MANAGEMENT, LLC

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

SIREN, L.L.C.

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

AVICENNA LIFE SCI MASTER FUND LP

By:		AVICENNA LIFE SCI MASTER GP LLC, its general partner

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		Chief Executive Officer

AVICENNA LIFE SCI MASTER GP LLC

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		Chief Executive Officer

ULYS, L.L.C.

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President


MR. RAYMOND DEBBANE

By:		/s/ Raymond Debbane

EXHIBIT INDEX


Exhibit Number		Title

1.		Joint Filing Agreement

Get the next $GOSS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GOSS

Date	Price Target	Rating	Analyst
6/25/2024	$9.00	Outperform	Oppenheimer
4/5/2024	$4.00	Outperform	Wedbush
7/27/2023	$8.00 → $1.25	Buy → Neutral	UBS
3/7/2023		Outperform → Mkt Perform	Raymond James
3/1/2023		Neutral	Guggenheim
12/7/2022		Neutral → Underweight	JP Morgan
12/7/2022	$3.00	Outperform → Neutral	SMBC Nikko
12/7/2022	$18.00 → $2.00	Overweight → Equal Weight	Barclays

More analyst ratings

$GOSS
Financials

Live finance-specific insights

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December
3/13/25 4:01:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
- $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. "Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study," said Faheem Hasnain, Co-
11/7/24 4:03:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. "Between the continued progress made in the enrollment of the Phase 3 PROSERA Study and the transformational collaboration agreement with the Chiesi Group, Gossamer has made great strides in the second quarter to ad
8/12/24 4:01:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care

$GOSS
Press Releases

Fastest customizable press release news feed in the world

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 258,750 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an induceme
5/7/25 5:30:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California. Poster Presentation Title: Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation Poster Number: P920 Session: A76 Finger on the Pulse: Cardiopulmonary Dysfunction in
5/7/25 4:01:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 55,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement
4/8/25 5:30:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care

$GOSS
Leadership Updates

Live Leadership Updates

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
12/5/23 7:01:00 AM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise
11/29/23 7:01:00 AM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),
10/3/23 4:08:00 PM ET
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care